SOPH
Bearish signalScored 2026-10-17 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
SOPHiA GENETICS S.A.
- Nom
- SOPHiA GENETICS S.A.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Information Services
- Bourse
- NASDAQ
- Capitalisation
- $625.7M
- Employés
- 415
- PDG
- Ross Muken
- Site web
- https://www.sophiagenetics.com
- Marché
- BLLNCERTDHHCATHSTMNRC
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 73 682 titres (~587 621,04 $ US)
- Insiders
- Camblong JurgiMuken RossHIBBS KATHY L
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,233,916
Avg sell (VWAP, 90d window) $7.77 vs last close $6.93 (-10.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,194,254 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-12
- Liquidity
- Thin $4,371,786/day · 20d vol
- Last synced
-
2026-10-20 21:11:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-13 | Xu Zhenyu | Sell · S · 10b5-1 | 4,000 | $7.18 | $28,727 | Form 4 |
| 2026-10-12 | Camblong Jurgi | Sell · S · 10b5-1 | 8,500 | $7.26 | $61,671 | Form 4 |
| 2026-10-12 | Menu Philippe | Sell · S · 10b5-1 | 5,000 | $7.26 | $36,303 | Form 4 |
| 2026-10-05 | CARDOZA GEORGE | Sell · S · 10b5-1 | 1,592 | $8.10 | $12,897 | Form 4 |
| 2026-10-05 | Camblong Jurgi | Sell · S · 10b5-1 | 40,172 | $8.13 | $326,526 | Form 4 |
| 2026-10-05 | Menu Philippe | Sell · S · 10b5-1 | 7,394 | $8.13 | $60,100 | Form 4 |
| 2026-10-05 | Muken Ross | Sell · S · 10b5-1 | 9,838 | $8.13 | $79,971 | Form 4 |
| 2026-10-05 | Puylaert Kevin | Sell · S | 31 | $7.92 | $246 | Form 4 |
| 2026-10-05 | Valente Manuela | Sell · S · 10b5-1 | 4,240 | $8.13 | $34,487 | Form 4 |
| 2026-10-05 | Van Well Daan | Sell · S · 10b5-1 | 6,168 | $8.12 | $50,100 | Form 4 |
| 2026-10-05 | Verma Abhimanyu | Sell · S · 10b5-1 | 5,284 | $8.12 | $42,929 | Form 4 |
| 2026-10-05 | Xu Zhenyu | Sell · S · 10b5-1 | 7,394 | $8.12 | $60,075 | Form 4 |
| 2026-09-21 | CARDOZA GEORGE | Sell · S · 10b5-1 | 774 | $8.33 | $6,447 | Form 4 |
| 2026-09-21 | Muken Ross | Sell · S · 10b5-1 | 422 | $8.33 | $3,515 | Form 4 |
| 2026-09-14 | Menu Philippe | Sell · S | 5,000 | $7.88 | $39,416 | Form 4 |
| 2026-09-14 | Xu Zhenyu | Sell · S · 10b5-1 | 4,000 | $7.88 | $31,538 | Form 4 |
| 2026-09-11 | Van Well Daan | Sell · S · 10b5-1 | 6,168 | $7.63 | $47,089 | Form 4 |
| 2026-09-10 | Camblong Jurgi | Sell · S · 10b5-1 | 8,500 | $7.66 | $65,120 | Form 4 |
| 2026-09-08 | HIBBS KATHY L | Sell · S · 10b5-1 | 6,250 | $8.13 | $50,818 | Form 4 |
| 2026-08-27 | Xu Zhenyu | Sell · S · 10b5-1 | 10,000 | $8.91 | $89,096 | Form 4 |
| 2026-08-25 | HIBBS KATHY L | Sell · S · 10b5-1 | 6,250 | $8.68 | $54,233 | Form 4 |
| 2026-08-25 | Menu Philippe | Sell · S · 10b5-1 | 5,000 | $8.68 | $43,396 | Form 4 |
| 2026-08-24 | Verma Abhimanyu | Sell · S · 10b5-1 | 5,000 | $8.80 | $44,000 | Form 4 |
| 2026-08-21 | Xu Zhenyu | Sell · S · 10b5-1 | 5,408 | $8.40 | $45,447 | Form 4 |
| 2026-08-20 | Xu Zhenyu | Sell · S · 10b5-1 | 4,592 | $8.41 | $38,609 | Form 4 |
| 2026-08-19 | Verma Abhimanyu | Sell · S · 10b5-1 | 5,000 | $8.20 | $41,000 | Form 4 |
| 2026-08-19 | Valente Manuela | Sell · S · 10b5-1 | 10,000 | $7.94 | $79,439 | Form 4 |
| 2026-08-19 | Xu Zhenyu | Sell · S · 10b5-1 | 10,000 | $7.94 | $79,427 | Form 4 |
| 2026-08-13 | Xu Zhenyu | Sell · S · 10b5-1 | 4,000 | $7.52 | $30,076 | Form 4 |
| 2026-08-12 | Menu Philippe | Sell · S · 10b5-1 | 5,000 | $7.52 | $37,580 | Form 4 |
| 2026-08-10 | Camblong Jurgi | Sell · S · 10b5-1 | 8,500 | $7.61 | $64,669 | Form 4 |
| 2026-08-07 | Camblong Jurgi | Sell · S · 10b5-1 | 20,000 | $7.23 | $144,540 | Form 4 |
| 2026-08-07 | Verma Abhimanyu | Sell · S · 10b5-1 | 5,000 | $7.60 | $38,000 | Form 4 |
| 2026-08-07 | Xu Zhenyu | Sell · S · 10b5-1 | 10,000 | $7.48 | $74,759 | Form 4 |
| 2026-08-05 | Xu Zhenyu | Sell · S · 10b5-1 | 3,000 | $7.00 | $21,013 | Form 4 |
| 2026-08-04 | Camblong Jurgi | Sell · S · 10b5-1 | 20,000 | $6.92 | $138,412 | Form 4 |
| 2026-08-04 | Verma Abhimanyu | Sell · S · 10b5-1 | 5,000 | $6.95 | $34,772 | Form 4 |
| 2026-08-04 | Xu Zhenyu | Sell · S · 10b5-1 | 10,000 | $6.92 | $69,168 | Form 4 |
| 2026-07-27 | Menu Philippe | Sell · S · 10b5-1 | 5,000 | $5.66 | $28,306 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-17 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
SOPH presents a deeply distressed financial profile with a net margin of -102%, unsustainable cash burn, and a deteriorating balance sheet that renders the liquidity score (25) and fundamental trend score (15)…
The first sentence of the analysis written for SOPH on 2026-10-17 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bearish signal
Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 1.96 · operating margin -92% — readings disagree
Suggested stop 6.51, nearest stored support minus 0.5 ATR(6.0% under the last close). Reward/risk to the next stored resistance is 4.23. Research, not advice. Not an order.
Recent news
- 2026-10-08 SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.
- 2026-10-08 Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.
- 2026-10-08 SOPHiA GENETICS (NASDAQ:SOPH) Insider Manuela Valente Sells 4,240 Shares of Stock SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) insider Manuela Valente sold 4,240 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $8.13, for a total transaction of $34,471.20. Following the transaction, the insider owned 206,210 shares of the company''s stock, valued at approximately
- 2026-10-08 SOPHiA GENETICS (NASDAQ:SOPH) CFO George Cardoza Sells 1,592 Shares of Company Stock SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) CFO George Cardoza sold 1,592 shares of the company''s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.10, for a total transaction of $12,895.20. Following the transaction, the chief financial officer directly owned 306,726 shares of the company''s
- 2026-10-06 SOPHiA GENETICS SA (NASDAQ:SOPH) Receives Average Rating of “Hold” from Analysts Shares of SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to
- 2026-09-18 SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last? SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 2026-08-27 When Unusual Volume Isn''t Noise: 3 Small-Caps Sending Signals The volume of shares traded in a session often gets a passing mention in the financial press until a stock experiences unusually high volume. That''s because volume can provide an important measure of the conviction behind a stock''s price movement.
- 2026-08-25 SOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next? SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $8.84 and last traded at $8.45, with a volume of 655541 shares trading hands. The stock had previously closed at $8.65. Analyst Ratings Changes SOPH has been the subject of a
- 2026-08-04 SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
- 2026-08-04 SOPHiA GENETICS Q2 Earnings Call Highlights SOPHiA GENETICS NASDAQ: SOPH reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.9% | 67.4% | 68.8% | 65.7% | 62.4% | |
| Ebit Margin | -95.7% | -91.1% | -124.9% | -182.8% | -180.1% | |
| Ebitda Margin | -83.3% | -77.9% | -111.5% | -171.1% | -171.2% | |
| Operating Profit Margin | -91.8% | -102.1% | -120.0% | -184.7% | -176.7% | |
| Pretax Profit Margin | -101.6% | -94.0% | -125.9% | -184.2% | -181.7% | |
| Continuous Operations Profit Margin | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | |
| Net Profit Margin | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | |
| Bottom Line Profit Margin | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | |
| Current Ratio | 1.961 | 3.709 | 4.156 | 7.320 | 9.889 | |
| Quick Ratio | 1.835 | 3.490 | 3.974 | 7.128 | 9.689 | |
| Solvency Ratio | -0.597 | -0.916 | -1.291 | -1.873 | -1.565 | |
| Cash Ratio | 1.391 | 2.993 | 3.460 | 6.017 | 6.746 | |
| Price To Earnings Ratio | -3.991 | -3.232 | -3.861 | -1.515 | -10.602 | |
| Price To Earnings Growth Ratio | -0.172 | 0.146 | 0.375 | -0.672 | -0.170 | |
| Forward Price To Earnings Growth Ratio | -0.172 | 0.146 | 0.375 | -0.672 | -0.170 | |
| Price To Earnings Diluted Ratio | -3.991 | -3.232 | -3.861 | -1.515 | -10.602 | |
| Price To Earnings Diluted Growth Ratio | -0.172 | 0.146 | 0.375 | -0.672 | -0.170 | |
| Price To Book Ratio | 6.690 | 2.093 | 2.014 | 0.660 | 2.831 | |
| Price To Sales Ratio | 4.082 | 3.099 | 4.890 | 2.776 | 19.276 | |
| Price To Free Cash Flow Ratio | -8.174 | -3.960 | -5.276 | -1.641 | -12.068 | |
| Price To Operating Cash Flow Ratio | -8.298 | -4.716 | -6.278 | -1.884 | -13.458 | |
| Debt To Assets Ratio | 0.386 | 0.193 | 0.090 | 0.069 | 0.041 | |
| Debt To Equity Ratio | 1.337 | 0.311 | 0.123 | 0.084 | 0.047 | |
| Debt To Capital Ratio | 0.572 | 0.237 | 0.109 | 0.077 | 0.045 | |
| Long Term Debt To Capital Ratio | 0.503 | 0.121 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.467 | 1.610 | 1.361 | 1.218 | 1.163 | |
| Working Capital Turnover Ratio | 1.276 | 0.704 | 0.443 | 0.225 | 0.236 | |
| Operating Cash Flow Ratio | -0.752 | -1.598 | -1.364 | -2.614 | -2.026 | |
| Operating Cash Flow Sales Ratio | -0.492 | -0.657 | -0.779 | -1.474 | -1.432 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | 1.191 | 1.190 | 1.148 | 1.115 | |
| Debt Service Coverage Ratio | -14.255 | -27.174 | -119.145 | -127.135 | -105.483 | |
| Interest Coverage Ratio | -15.574 | -34.798 | -127.255 | -137.438 | -108.646 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.603 | -1.426 | -2.611 | -4.186 | -4.437 | |
| Capital Expenditure Coverage Ratio | -66.221 | -5.238 | -5.265 | -6.752 | -8.685 | |
| Dividend Paid And Capex Coverage Ratio | -66.221 | -5.238 | -5.265 | -6.752 | -8.685 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.785 | -2.990 | -2.879 | 0.154 | -8.663 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.9% | ▼-5.5% | ▼-3.4% |
| Ebit Margin | -95.7% | ▼-4.6% | ▲39.2% |
| Ebitda Margin | -83.4% | ▼-5.5% | ▲39.7% |
| Operating Profit Margin | -91.8% | ▲10.3% | ▲43.3% |
| Pretax Profit Margin | -101.6% | ▼-7.6% | ▲35.9% |
| Continuous Operations Profit Margin | -102.2% | ▼-6.3% | ▲35.9% |
| Net Profit Margin | -102.2% | ▼-6.3% | ▲35.9% |
| Bottom Line Profit Margin | -102.2% | ▼-6.3% | ▲35.9% |
| Current Ratio | 1.961 | ▼-1.748 | ▼-3.446 |
| Quick Ratio | 1.835 | ▼-1.655 | ▼-3.388 |
| Solvency Ratio | -0.597 | ▲0.319 | ▲0.651 |
| Cash Ratio | 1.391 | ▼-1.602 | ▼-2.730 |
| Price To Earnings Ratio | -3.991 | ▼-0.760 | ▲0.648 |
| Price To Earnings Growth Ratio | -0.172 | ▼-0.318 | ▼-0.074 |
| Forward Price To Earnings Growth Ratio | -0.172 | ▼-0.318 | ▼-0.074 |
| Price To Earnings Diluted Ratio | -3.991 | ▼-0.760 | ▲0.648 |
| Price To Earnings Diluted Growth Ratio | -0.172 | ▼-0.318 | ▼-0.074 |
| Price To Book Ratio | 6.690 | ▲4.597 | ▲3.833 |
| Price To Sales Ratio | 4.082 | ▲0.983 | ▼-2.743 |
| Price To Free Cash Flow Ratio | -8.174 | ▼-4.215 | ▼-1.950 |
| Price To Operating Cash Flow Ratio | -8.298 | ▼-3.582 | ▼-1.371 |
| Debt To Assets Ratio | 0.386 | ▲0.192 | ▲0.230 |
| Debt To Equity Ratio | 1.337 | ▲1.026 | ▲0.956 |
| Debt To Capital Ratio | 0.572 | ▲0.335 | ▲0.364 |
| Long Term Debt To Capital Ratio | 0.503 | ▲0.383 | ▲0.378 |
| Financial Leverage Ratio | 3.467 | ▲1.857 | ▲1.703 |
| Working Capital Turnover Ratio | 1.276 | ▲0.571 | ▲0.699 |
| Operating Cash Flow Ratio | -0.752 | ▲0.845 | ▲0.918 |
| Operating Cash Flow Sales Ratio | -0.492 | ▲0.165 | ▲0.475 |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | ▼-0.176 | ▼-0.117 |
| Debt Service Coverage Ratio | -14.255 | ▲12.919 | ▲64.383 |
| Interest Coverage Ratio | -15.574 | ▲19.224 | ▲69.168 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.603 | ▲0.823 | ▲2.050 |
| Capital Expenditure Coverage Ratio | -66.221 | ▼-60.984 | ▼-47.789 |
| Dividend Paid And Capex Coverage Ratio | -66.221 | ▼-60.984 | ▼-47.789 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.785 | ▼-1.795 | ▼-0.952 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $315.4M | $202.0M | $305.0M | $132.0M | $779.7M | |
| Enterprise value | $308.1M | $151.8M | $200.3M | -$12.5M | $599.8M | |
| EV / Sales | 3.99x | 2.33x | 3.21x | -0.26x | 14.83x | |
| EV / Op. cash flow | -8.11x | -3.54x | -4.12x | 0.18x | -10.35x | |
| EV / Free cash flow | -7.99x | -2.98x | -3.47x | 0.16x | -9.28x | |
| EV / EBITDA | -4.79x | -2.99x | -2.88x | 0.15x | -8.66x | |
| Net debt / EBITDA | 0.11x | 0.99x | 1.50x | 1.78x | 2.60x | |
| Current ratio | 1.96x | 3.71x | 4.16x | 7.32x | 9.89x | |
| Income quality | 0.48x | 0.70x | 0.62x | 0.80x | 0.79x | |
| Graham net-net | -$0 | $0 | $1 | $2 | $4 | |
| Tax burden | 100.7% | 102.0% | 100.6% | 99.8% | 100.2% | |
| Interest burden | 106.2% | 103.2% | 100.8% | 100.7% | 100.9% | |
| Working capital | $48.6M | $72.6M | $112.4M | $169.4M | $254.3M | |
| Invested capital | $102.5M | $121.0M | $162.7M | $210.8M | $285.9M | |
| Return on assets | -48.3% | -40.2% | -38.3% | -35.9% | -23.0% | |
| Operating ROA | -44.5% | -36.8% | -33.3% | -31.1% | -31.6% | |
| Return on tangible assets | -61.9% | -49.5% | -44.1% | -39.1% | -24.2% | |
| Return on equity | -167.6% | -64.8% | -52.2% | -43.7% | -26.8% | |
| Return on invested capital | -61.3% | -50.9% | -43.1% | -39.9% | -24.4% | |
| Return on capital employed | -62.8% | -51.8% | -43.9% | -40.5% | -24.5% | |
| Earnings yield | -25.0% | -30.9% | -25.9% | -66.2% | -9.4% | |
| Free cash flow yield | -12.2% | -25.3% | -19.0% | -60.9% | -8.3% | |
| Capex / Op. cash flow | -1.5% | -19.1% | -19.0% | -14.8% | -11.5% | |
| Capex / Depreciation | 6.0% | 95.1% | 110.7% | 186.3% | 184.8% | |
| Capex / Sales | 0.7% | 12.5% | 14.8% | 21.8% | 16.5% | |
| SG&A / Sales | 110.2% | 117.1% | 131.0% | 176.8% | 173.6% | |
| R&D / Sales | 43.4% | 52.7% | 59.3% | 74.4% | 65.7% | |
| Stock comp / Sales | 0.0% | 25.3% | 24.4% | 28.6% | 21.0% | |
| Intangibles / Total assets | 22.0% | 18.7% | 13.2% | 8.2% | 4.9% | |
| Days sales outstanding | 88d | 49d | 89d | 62d | 64d | |
| Days payables outstanding | 66d | 33d | 42d | 49d | 56d | |
| Operating cycle | 166d | 150d | 211d | 177d | 201d | |
| Cash conversion cycle | 100d | 116d | 168d | 129d | 145d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+56.2%EV / Sales ▲+71.3%EV / EBITDA ▼-60.0%EV / Op. cash flow ▼-4.563Earnings yield ▲+0.059
Profitability
Return on equity ▼-1.028Return on assets ▼-0.081Return on invested capital ▼-0.104Return on capital employed ▼-0.110Operating ROA ▼-0.077Income quality ▼-0.218Tax burden ▼-0.013
Efficiency
Days sales outstanding ▲+38.847Days payables outstanding ▲+32.651Operating cycle ▲+16.684Cash conversion cycle ▼-15.968Capex / Sales ▼-0.118R&D / Sales ▼-0.093
Balance-sheet strength
Current ratio ▼-1.748Net debt / EBITDA ▼-0.876Working capital ▼-24051000.000Invested capital ▼-18488000.000Intangibles / Total assets ▲+0.033
Change over 5 years
Valuation
Market cap ▼-59.5%EV / Sales ▼-73.1%EV / EBITDA ▲+44.8%EV / Op. cash flow ▲+2.246Earnings yield ▼-0.156
Profitability
Return on equity ▼-1.408Return on assets ▼-0.253Return on invested capital ▼-0.370Return on capital employed ▼-0.383Operating ROA ▼-0.129Income quality ▼-0.307Tax burden ▲+0.004
Efficiency
Days sales outstanding ▲+23.547Days payables outstanding ▲+9.846Operating cycle ▼-35.067Cash conversion cycle ▼-44.913Capex / Sales ▼-0.157R&D / Sales ▼-0.223
Balance-sheet strength
Current ratio ▼-7.928Net debt / EBITDA ▼-2.485Working capital ▼-205701000.000Invested capital ▼-183391000.000Intangibles / Total assets ▲+0.171